ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
September 16, 2024 08:53 ET
|
ANI Pharmaceuticals, Inc.
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with...
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
September 16, 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the...
ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution
September 13, 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan...
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
September 11, 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.; Alimera Sciences, Inc.
PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly...
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
September 10, 2024 14:09 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously...
ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes
August 13, 2024 16:05 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal...
ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering
August 07, 2024 21:44 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal...
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering
August 07, 2024 07:00 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its intention to offer, subject to market and other conditions,...
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
August 06, 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4%...
ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET
July 31, 2024 07:00 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2024 financial...